Brian Kelly, PhD, DABCC, FADLM

Adjunct Assistant Professor, University of Utah School of Medicine

Specialties

• Clinical toxicology: sports drug testing
• Laboratory management: regulatory compliance

Education

• Doctorate Degree—Biochemistry, University of Utah
• Fellowship—Forensic Testing and Sports Anti-Doping Research, Sports Medicine Research and Testing Laboratory
• Fellowship—Clinical Chemistry and Laboratory Medicine, University of Virginia

Current/Past Roles

• Clinical Toxicology Specialist, ARUP (past)
• Owner, BNK Clinical Laboratory Consulting, LLC (current)

Certification/Affiliations

• Diplomate—American Board of Clinical Chemistry
• Certification of Qualification, New York State Department of Health
• Fellow of the Association of Diagnostics & Laboratory Medicine

Research Interests

• Sports drug testing
• Clinical laboratory management

Recent Publications

• Boyd JM, Kelly BN, McMillin GA . Prevalence of gabapentinoid and opioid copositives in a reference laboratory patient population. J Appl Lab Med. 2024;9(4):861-863.
• Kelly BN. UTI detection by PCR: improving patient outcomes. J Mass Spectrom Adv Clin Lab. 2023;28:60-62.
• McMillin GA, Johnson-Davis KL, Kelly BN, et al. Impact of the opioid epidemic on drug testing. Ther Drug Monit. 2021;43(1):14-24.
• Snozek CLH, Baskin LB, Boyd JM, et al. How can routine clinical laboratories keep up with the opioid crisis? Clin Chem. 2021;67(2):338-344.
• Yang YK, Johnson-Davis KL, Kelly BN, et al. Demand for interpretation of a urine drug testing panel reflects the changing landscape of clinical needs; opportunities for the laboratory to provide added clinical value. J Appl Lab Med. 2020;5(5):858-868.